Search Results - "Scheliga, A."

REAL-WORLD ANALYSIS OF PATIENTS WITH CLL TREATED WITH IBRUTINIB: A RETROSPECTIVE ANALYSIS OF THE BRAZILIAN REGISTRY OF CLL by V Pfister, FM Marques, R Santucci, V Buccheri, G Ribeiro, VLP Figueiredo, N Hamerschlak, A Costa, T Silveira, A Scheliga, L Perobelli, CS Chiattone, C Arrais-Rodrigues

“…Introduction: Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, is associated with increased survival and prolonged response, even in high-risk scenarios,…”
Get full text

Association of social network and social support with health-related quality of life and fatigue in long-term survivors of Hodgkin lymphoma by Soares, A., Biasoli, I., Scheliga, A., Baptista, R. L., Brabo, E. P., Morais, J. C., Werneck, G. L., Spector, N.

“…Purpose As the number of survivors of Hodgkin’s lymphoma (HL) increases, there has been a growing interest in long-term treatment-related side effects and…”
Get full text

AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO by Gribben, J., Trneny, M., Izutsu, K., Fowler, N.H., Hong, X., Zhang, H., Offner, F., Scheliga, A., Nowakowski, G., Pinto, A., Re, F., Fogliatto, L., Scheinberg, P., Flinn, I., Moreira, C., Czuczman, M., Kalambakas, S., Fustier, P., Wu, C., Leonard, J.

Get full text

AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS by Leonard, J., Trneny, M., Izutsu, K., Fowler, N., Hong, X., Zhang, H., Offner, F., Scheliga, A., Nowakowski, G., Pinto, A., Re, F., Fogliatto, L., Scheinberg, P., Flinn, I., Moreira, C., Czuczman, M., Kalambakas, S., Fustier, P., Wu, C., Gribben, J.

Get full text

HEALTH‐RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2) VERSUS R PLUS PLACEBO by Leonard, J.P., Trněny, M., Izutsu, K., Fowler, N.H., Hong, X., Zhang, H., Offner, F., Scheliga, A., Nowakowski, G., Pinto, A., Re, F., Fogliatto, L.M., Scheinberg, P., Flinn, I.W., Moreira, C., Tabah, A., Abouzaid, S., Kalambakas, S., Fustier, P., Wu, C., Gribben, J.G.

Get full text

CD10 and Bcl-2 expression combined with the International Prognostic Index can identify subgroups of patients with diffuse large-cell lymphoma with very good or very poor prognoses by Biasoli, I, Morais, J C, Scheliga, A, Milito, C B, Romano, S, Land, M, Pulcheri, W, Spector, N

“…Aims : Diffuse large B‐cell lymphoma (DLBCL) is characterized by marked biological heterogeneity. The identification of reproducible parameters that can be…”
Get full text

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group by Pfreundschuh, Michael, Trümper, Lorenz, Osterborg, Anders, Pettengell, Ruth, Trneny, Marek, Imrie, Kevin, Ma, David, Gill, Devinder, Walewski, Jan, Zinzani, Pier-Luigi, Stahel, Rolf, Kvaloy, Stein, Shpilberg, Ofer, Jaeger, Ulrich, Hansen, Mads, Lehtinen, Tuula, López-Guillermo, Armando, Corrado, Claudia, Scheliga, Adriana, Milpied, Noel, Mendila, Myriam, Rashford, Michelle, Kuhnt, Evelyn, Loeffler, Markus

“…The role of rituximab in combination with different CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone)-like chemotherapy regimens in young…”
Get more information

POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO (AUGMENT) by Thieblemont, C., Leonard, J., Trneny, M., Izutsu, K., Fowler, N., Hong, X., Zhang, H., Offner, F., Scheliga, A., Nowakowski, G., Pinto, A., Re, F., Fogliatto, L., Scheinberg, P., Flinn, I., Moreira, C., Czuczman, M., Kalambakas, S., Fustier, P., Wu, C., Gribben, J.

Get full text

PF483 EFFICACY WAS IMPROVED WITH LENALIDOMIDE/RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH FOLLICULAR LYMPHOMA IRRESPECTIVE OF POD24 STATUS IN THE PHASE III AUGMENT STUDY by Leonard, J.P., Trneny, M., Izutsu, K., Fowler, N.H., Hong, X., Zhang, H., Offner, F., Scheliga, A., Nowakowski, G., Pinto, A., Re, F., Fogliatto, L.M., Scheinberg, P., Flinn, I., Moreira, C., Czuczman, M., Kalambakas, S.A., Fustier, P., Wu, C., Gribben, J.

“…Background: Less favorable prognosis and survival have been reported for follicular lymphoma (FL) patients who relapse within 2 years of initial…”
Get full text

PS1252 PATIENTS WITH RELAPSED/REFRACTORY INDOLENT NON‐HODGKIN LYMPHOMA WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO (AUGMENT) by Gribben, J., Trneny, M., Izutsu, K., Fowler, N.H., Hong, X., Zhang, H., Offner, F., Scheliga, A., Nowakowski, G., Pinto, A., Re, F., Fogliatto, L.M., Scheinberg, P., Flinn, I., Moreira, C., Czuczman, M., Kalambakas, S.A., Fustier, P., Wu, C., Leonard, J.P.

“…Background: An unmet need remains in patients with indolent lymphoma following relapse; more effective and tolerable therapies are needed to improve outcomes…”
Get full text

PS1262 POST HOC ANALYSIS OF THE AUGMENT PHASE III RANDOMIZED STUDY OF LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO IN PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA by Thieblemont, C., Leonard, J.P., Trneny, M., Izutsu, K., Fowler, N.H., Hong, X., Zhang, H., Offner, F., Scheliga, A., Nowakowski, G., Pinto, A., Re, F., Fogliatto, L.M., Scheinberg, P., Flinn, I., Moreira, C., Czuczman, M., Kalambakas, S.A., Fustier, P., Wu, C., Gribben, J.

“…Background: Lenalidomide plus rituximab (R2) has established efficacy and a tolerable safety profile in patients with previously untreated and…”
Get full text

Prognostic factors for patients with lymphoma requiring intensive care by Scheliga, A., Vieira, F. M., Spector, N., Romano, S., Salluh, J. I., Bello, R. D., Soares, M.

“…Abstract only 17519 Background: Prognosis of patients (pts) with hematological malignancies (HM) in the intensive care unit (ICU) seems to be improving,…”
Get full text

POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO (AUGMENT) by Thieblemont, C, Leonard, J, Trneny, M, Izutsu, K, Fowler, N, Hong, X, Zhang, H, Offner, F, Scheliga, A, Nowakowski, G, Pinto, A, F Re, Fogliatto, L, Scheinberg, P, Flinn, I, Moreira, C, Czuczman, M, Kalambakas, S, Fustier, P, C Wu, Gribben, J

Get full text

VAD (vincristine, doxorubicin and high-dose dexamethasone) administered as intravenous bolus (IVB) injection as first-line treatment in multiple myeloma (MM) by Vendette, A. C., Ferreira, C. G., Small, I. A., Reinhard, B., Scheliga, A.

“…Abstract only…”
Get full text

VAD (vincristine, doxorubicin and high-dose dexamethasone) administered as intravenous bolus (IVB) injection as first-line treatment in multiple myeloma (MM) by Vendette, A. C., Ferreira, C. G., Small, I. A., Reinhard, B., Scheliga, A.

“…Abstract only…”
Get full text

Efficacy and time to next treatment following lenalidomide/rituximab (R 2 ) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT) by Gribben, John G., Izutsu, Koji, Fowler, Nathan Hale, Hong, Xiaonan, Zhang, Huilai, Offner, Fritz, Scheliga, Adriana A. S., Nowakowski, Grzegorz S., Pinto, Antonio, Re, Francesca, Fogliatto, Laura Maria, Scheinberg, Phillip, Flinn, Ian, Moreira, Cláudia, Kalambakas, Stacey Anastasia, Fustier, Pierre, Wu, Chengqing (Alan), Leonard, John Paul

“…Abstract only 7514 Background: Relapse is expected in treated indolent lymphoma patients, and an unmet need exists to prolong remission with effective…”
Get full text